Article citationsMore>>
Smith, J.A. (2012) Commentary on “Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-Up”. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team. Collaborators (18) Buring JE, Alberts D, Carter HB, Chodak G, Hawk E, Malm H, Mayer RJ, Piantadosi S, Silvestri GA, Thompson IM, Westhoff CL, Kahn JP, Levin B, DeMets D, O’Fallon JR, Porter AT, Ashton MM, Black WC, Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO 63130, USA: J. Natl Cancer Inst 2012; 104(2): 125-32. Epub January 6, 2012. Urologic Oncology, 30, 960-961.
https://doi.org/10.1016/j.urolonc.2012.08.006
has been cited by the following article:
-
TITLE:
Curative 3D Conformal Radiotherapy of Non-Operated Prostate Adenocarcinoma at Pointe-a-Pitre University Hospital (Guadeloupe): About 29 Cases
AUTHORS:
Ibrahima Thiam, Kanta Ka, Awa Sadikh Badiane, Mouhamadou Bachir Bâ, El Hadj Amadou Sall, Boucar Ndong, Papa Ahmet Fall, Mamadou Moustapha Dieng, Papa Macoumba Gaye
KEYWORDS:
Prostate Cancer, 3D Conformal Radiotherapy, Survival
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.12 No.5,
May
27,
2021
ABSTRACT: Context: Technological advances have improved the toxicities of radiotherapy. We
are evaluating the 3D technique in prostate cancer. Materials and Methods: Retrospective study from January 2015 to December 2015 with 29 files. Survival
was calculated by Kaplan-Meier method. Results: We collected 29 patient
records over the study period. The median age was 75 years with the following
extremes: 54 years and 83 years. The median PSA level was 12 ng/ml with a range
of 3.05 to 79 ng/ml. Gleason score analysis showed 6 patients (20.69%) with a
score of 6 (3 + 3), 23 patients (79.31%) with a score of 7 including 12
patients (41.38%) with grade 3 and 11 patients (37.93%) with grade 4. The
median dose delivered was 74 Gy, with a mean dose of 73.79 Gy and extremes of
70 Gy for the minimum and 76 Gy for the maximum. Hormone therapy was combined
with radiotherapy in 17 patients (58.62%). Seven
patients (24.14%) had grade 1 acute bladder toxicity and one patient (3.45%) had grade 2 acute toxicity. Late
bladder toxicity was grade 1 in 5 patients (17.24%), grade 2 in 3
patients (10.34%) and grade 3 in 1 patient (3.45%). Late rectal toxicity, grade 2 in 3 patients (10.34%), grade 3 in 1
patient, was noted. Overall survival at 2 years was 100% and 89.65% at 5 years.
Relapse-free survival at 2 years was
82.76% and 62.07% at 5 years. There were 3 deaths (10.34%) of which only one
was related to prostate cancer. Conclusion: Radiotherapy, like surgery, is a fundamental option
for the treatment of prostate cancers, particularly those that are
locally advanced. It is gaining in importance with the improvement of
techniques (IMRT, VMAT…) and new fractionations which contribute to the
reduction of toxicities and the comfort of patients (shorter spread).
Related Articles:
-
Drew Freilich, Eric Moskowitz, Nicholas Feuer, Muhammad Choudhury, John Phillips, Sensuke Konno
-
Munekayi Padingani, Gladys Marape, Zanele Hwalima, Notion Gombe, Ms T. Juru
-
Samuel Deem, Brian DeFade, Josh Lohri, James P. Tierney, Asmita Modak, Mary Emmett
-
Mohamed Serag, Mohamed Mahmoud, Ahmed Seleem, Mervat Elnagar
-
Fuat Demirkiran